1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor

Prostaglandin Receptor

Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101952
    Prostaglandin E2
    Activator 99.76%
    Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
    Prostaglandin E2
  • HY-101840
    EIPA
    Inhibitor 99.73%
    EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
    EIPA
  • HY-B0131
    Prostaglandin E1
    Agonist 99.76%
    Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases.
    Prostaglandin E1
  • HY-108566
    U-46619
    Agonist ≥99.0%
    U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation.
    U-46619
  • HY-101988
    Prostaglandin D2
    Activator 99.5%
    Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.
    Prostaglandin D2
  • HY-B0813R
    Treprostinil (diethanolamine) (Standard)
    Agonist
    Geniposide (Standard) is the analytical standard of Geniposide. This product is intended for research and analytical applications. Geniposide is an iridoid glucoside extracted from Gardenia jasminoidesEllis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.
    Treprostinil (diethanolamine) (Standard)
  • HY-159704
    9-Keto-latanoprost
    Control
    9-keto latanoprost is a derivative of the F-prostaglandin (FP) receptor agonist Latanoprost (HY-B0577).
    9-Keto-latanoprost
  • HY-137585
    17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α
    Control
    17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α is a derivative of Bimatoprost acid (HY-125774).
    17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α
  • HY-12956
    Dinoprost
    Agonist 99.63%
    Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
    Dinoprost
  • HY-B0195
    Tranilast
    Inhibitor 99.58%
    Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
    Tranilast
  • HY-18966
    PF-04418948
    Antagonist 99.40%
    PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.
    PF-04418948
  • HY-50901
    ONO-AE3-208
    Antagonist 98.65%
    ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
    ONO-AE3-208
  • HY-B0577
    Latanoprost
    Agonist 99.85%
    Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea.
    Latanoprost
  • HY-100441
    Treprostinil
    Inhibitor 99.98%
    Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
    Treprostinil
  • HY-101840A
    EIPA hydrochloride
    Inhibitor 98.31%
    EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
    EIPA hydrochloride
  • HY-14870
    Selexipag
    Agonist 99.86%
    Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
    Selexipag
  • HY-103088
    Palupiprant
    Antagonist 99.60%
    Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. Palupiprant exhibits anti-tumor activities.
    Palupiprant
  • HY-A0096
    Iloprost
    Agonist 99.76%
    Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.
    Iloprost
  • HY-15274
    L-798106
    Antagonist 99.81%
    L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has ?micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM, respectively.
    L-798106
  • HY-10835
    DG-041
    Antagonist ≥99.0%
    DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier.
    DG-041
Cat. No. Product Name / Synonyms Application Reactivity

DP

EP

FP

IP

TXA2/TP

TXB2

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Prostaglandin Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators
Product NameDPEPFPIPTXA2/TPTXB2Purity    
Prostaglandin E2 
EP
    99.76%
Prostaglandin E1 
EP
    99.76%
U-46619    
TXA2/TP
 ≥99.0%
Prostaglandin D2
DP
     99.5%
Dinoprost  
FP Receptor
   99.63%
Tranilast
DP2, IC50: 0.1 mM
     99.58%
PF-04418948 
EP2, IC50: 16 nM
    99.40%
ONO-AE3-208 
EP4, Ki: 1.3 nM
EP3, Ki: 30 nM
FP, Ki: 790 nM
 
TP Receptor, Ki: 2400 nM
 98.65%
Latanoprost  
FP Receptor
   99.85%
Treprostinil  
FP Receptor, Ki: 4680 nM
IP Receptor, EC50: 1.9 nM
IP Receptor, Ki: 32.1 nM
TP Receptor, EC50: 919 nM
 99.98%
Selexipag   
hIP, Ki: 260 nM
  99.86%
Iloprost   
IP
  99.76%
L-798106 
EP3, IC50: 0.3 nM
EP4, IC50: 916 nM
EP1, IC50: >5000 nM
EP2, IC50: >5000 nM
    99.81%
DG-041 
EP3, IC50: 4.6-8.1 nM
    ≥99.0%
16,16-Dimethyl prostaglandin E2 
EP2
EP4
    ≥99.0%
L-161982 
EP4
    99.04%
Laropiprant
DP, Ki: 0.57 nM
   
TP Receptor, Ki: 2.95 nM
 99.93%
Grapiprant 
dog EP4, IC50: 35 nM
dog EP4, Ki: 24 nM
    99.57%
Asapiprant
DP1, Ki: 0.44 nM
     99.53%
RO1138452   
Rat I2 Receptor, IC50: 7 nM
Rat I2 Receptor, pKi: 8.33
  ≥98.0%
GW627368 
EP
    99.81%
Ginsenoside Ro    
TXA2
 99.81%
Travoprost  
FP
   99.99%
Ramatroban
hDP2, IC50: 113 nM
hDP2, IC50: 33.4 μM
   
hTP, IC50: 14 nM
 99.10%
Prostaglandin E2-d4 
EP
    99.90%
Cefminox sodium   
IP Receptor
  99.83%
Omidenepag 
hEP4, IC50: 5480 nM
hEP2, IC50: 10 nM
hEP2, EC50: 1.1 nM
    99.67%
L-902688 
EP4, Ki: 0.38 nM
EP4, EC50: 0.6 nM
    ≥99.0%
Seratrodast    
TXA2/TP
 98.86%
Nedocromil
PGD2
     98.75%
NTP42    
TXA2
 98.58%
MRE-269   
IP Receptor
  99.91%
Ebopiprant  
Human FP Receptor, Ki: 1 nM
Rat FP Receptor, Ki: 26 nM
   98.65%
Pectolinarin 
EP
    99.89%
Fevipiprant
DP2, Kd: 1.14 nM
     99.38%
AZD1981
DP
     99.37%
Beraprost sodium   
IP
  99.88%
Omidenepag isopropyl 
EP2
    99.20%
TG4-155 
EP2, Ki: 9.9 nM
    99.91%
Prostaglandin J2
hDP, Ki: 0.9 nM
hCRTH2, Ki: 6.6 nM
hEP1, Ki: 15.678 μM
hEP2, Ki: 989 nM
hEP3, Ki: 319 nM
hEP4, Ki: 1065 nM
hFP, Ki: 553 nM
hIP, Ki: >25 μM
hTP, Ki: 6426 nM
 98.10%
Timapiprant
DP
     99.48%
Prostaglandin E2 (Standard) 
EP
    
p-Hydroxycinnamic acid     
TXB2, IC50: 371 μM
99.94%
CJ-42794 
EP, EC50: 10 nM
    98.96%
Treprostinil sodium
DP1, EC50: 0.6±0.1 nM
DP1, Ki: 4.4 nM
EP2, EC50: 6.2±1.2 nM
EP2, Ki: 3.6 nM
EP4, Ki: 826 nM
EP3, Ki: 2505 nM
EP1, Ki: 212 nM
EP1, EC50: 285 nM
EP3, EC50: 68.9 nM
EP4, EC50: 181 nM
FP Receptor, Ki: 4680 nM
IP Receptor, EC50: 1.9 nM
IP Receptor, Ki: 32.1 nM
TP Receptor, EC50: 919 nM
 99.78%
MF498 
EP4, Ki: 0.7 nM
    99.26%
BW 245C
DP
     99.73%
SC-51322 
EP2, pA2: 8.1
    98.90%
L 888607
DP, Ki: 0.8 nM
 
FP Receptor, Ki: 10018 nM
IP Receptor, Ki: 14434 nM
TP Receptor, Ki: 283 nM
 99.87%
Ozagrel    
TXA2
 99.74%
Ridogrel 
EP
    99.64%
Carbacyclin   
PGI2 Receptor
  98.00%
EP2 receptor antagonist-2 
EP
    98.69%
Latanoprost acid  
FP
   99.62%
Evatanepag 
EP2
    99.78%
MF-766 
EP4, Ki: 0.23 nM
    99.69%
Licarin A
DP
     98.48%
(+)-Cloprostenol  
PGF
   99.28%
CAY10471 Racemate
CRTH2, Ki: 0.6 nM
     99.00%
Dinoprost tromethamine salt  
FP Receptor
   ≥98.0%
EP3 antagonist 3 
EP3, pKi: 8.3
    99.52%
Setipiprant
hCRTH2, IC50: 6 nM
hDP1, IC50: 1290 nM
EP2, IC50: 2600 nM
    98.23%
Sulprostone 
EP3
    ≥99.0%
Epibetulinic acid 
EP2, IC50: 0.6 μM
    ≥98.0%
PDC31  
FP Receptor, Ki: ~30 nM
   99.76%
Ozagrel hydrochloride    
TXA2/TP
 99.68%
SC 51089 free base 
EP1, Ki: 1.3 μM
EP3, Ki: 17.5 μM
FP, Ki: 61.1 μM
 
TP, Ki: 11.2 μM
 98.64%
EP2 receptor antagonist-1 
EP2
    99.45%
EP4 receptor agonist 2 
EP4, EC50: 0.8 nM
EP2, Ki: >100000 nM
EP3, Ki: 38000 nM
EP4, Ki: 3.1 nM
    ≥99.0%
Ralinepag
hDP1, EC50: 850 nM
  
hIP, EC50: 8.5 nM
rIP, EC50: 530 nM
  99.79%
L-826266 
EP3
    ≥98.0%
BI-671800
hCRTH2, IC50: 4.5 nM
mCRTH2, IC50: 3.7 μM
     99.36%
Taprenepag isopropyl 
EP2
    99.23%
BAY-6672 hydrochloride  
FP
   98.44%
BAY 73-1449   
IP Receptor, IC50: <0.1 nM
  99.99%
Ozagrel sodium    
TXA2
 99.98%
MK-7246
DP, Ki: 2.5 nM
   
TP, Ki: 3804 nM
 99.63%
Treprostinil palmitil
DP
     99.62%
SC-19220 
EP
    99.71%
Picotamide    
TXA2/TP
 99.76%
BW A868C
DP2
     99.00%
AAT-008 
EP4, Ki: 0.97 nM
EP4, IC50: 6.1 nM
    98.55%
Misoprostol acid 
EP
    ≥99.0%
CAY10580 
EP4, Ki: 35 nM
EP2, Ki: 3000 nM
EP3, Ki: 2000 nM
EP1, Ki: >3000 nM
    
Darbufelone mesylate  
PGF
   99.65%
Pexopiprant
DP2, Ki: <100 nM
     99.40%
PROTAC(H-PGDS)-7
DP
     99.42%
EP4-IN-1 
EP4
    99.94%
15-keto-Prostaglandin F2a  
FP
   99.2%
AMG-009
DP, IC50: 12 nM
CRTH2, IC50: 3 nM
     98.08%
PGN-9856 
EP2, pEC50: ≥ 8.5
EP2, pKi: ≥ 8.3
    98.90%
Pizuglanstat
DP
     99.70%
BAY-1316957 
human EP4-R, IC50: 15.3 nM
    99.73%
Aganepag isopropyl 
EP
    98.61%
Nedocromil sodium
DP
     
KW-8232 
EP
    98.10%
Tafluprost acid 
EP3, IC50: 67 nM
Human FP Receptor, Ki: 0.4 nM
Human FP Receptor, EC50: 0.53 nM
   99.80%
Daltroban    
TXA2
 98.1%
Carboprost  
FP
   99.83%
Tiaprost  
PGF
   ≥98.0%
KP496    
TXA2 Receptor
 99.79%
BGC-20-1531 free base 
EP4, pKd: 7.6
    98.05%
KW-8232 free base 
EP
    
Aganepag 
EP2, EC50: 0.19 nM
    99.71%
Treprostinil diethanolamine
DP1, Ki: 4.4 nM
EP2, Ki: 3.6 nM
EP1, Ki: 212 nM
EP4, Ki: 826 nM
EP3, Ki: 2505 nM
FP, Ki: 4680 nM
IP, Ki: 32.1 nM
  99.44%
Taprostene   
IP
  
17-Phenyl-ω-trinor-PGE2 
EP1
EP3
    ≥98.0%
L 888607 Racemate
DP1, Ki: 132 nM
   
TP, Ki: 17 nM
 99.81%
Prostaglandin D2-d9
DP
     ≥99.0%
Selexipag-d7   
IP
  98.44%
Rivenprost 
EP4, Ki: 0.7 nM
    ≥99.0%
CAY10471
CRTH2
     
SC 51089 
EP1, Ki: 1.3 μM
EP3, Ki: 17.5 μM
FP, Ki: 61.1 μM
 
TP, Ki: 11.2 μM
 
GSK-269984A 
EP1, pIC50: 7.9
    99.74%
Carboprost tromethamine  
FP
   99.85%
ONO-8711 
EP
    
Tranilast sodium
DP2, IC50: 0.1 mM
     
Iloprost-d4   
IP
  
Sulotroban    
TXA2 Receptor
 
EP4 receptor antagonist 2 
EP4, IC50: 7.8 nM
    
Ifetroban    
TXA2/TP
 99.65%
Cicaprost   
IP
  
BAY-6672  
FP
   
Laropiprant sodium
DP, Ki: 0.57 nM
   
TP, Ki: 2.95 nM
 
MK-8318
DP, Ki: 5.0 nM
     
GSK345931A 
EP1
    
Prostaglandin E1-d9 
EP
    
(R)-Vorbipiprant 
hEP4, Ki: 16.6 nM
    
Selexipag-d6   
IP
  
L-644698
hDP receptor, Ki: 0.9 nM
hEP2, Ki: 267 nM
hEP3, Ki: 3730 nM
hEP4, Ki: 9280 nM
    
MK-447   
PGI2
  
ASP7657 free base 
hEP4, IC50: 2.21 nM
rat EP4, IC50: 6.02 nM
    
Nocloprost 
EP1
EP3
    
Travoprost (Standard)  
FP
   
I-SAP    
TXA2 Receptor
 
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide   
PGI2
  
Treprostinil-13C2,d
DP
EP
    
Prostaglandin E2-d9 
EP
    
Prostaglandin E1 (Standard) 
EP
    
EP4 receptor agonist 1 
hEP4, pEC50: 6.3
    
Cloprostenol isopropyl ester  
FP
   
Misoprostol acid-d5 
EP
    
TP-16 
EP4, IC50: 2.1 nM
    
AGN 210676
hDP receptor, EC50: 7749 nM
EP2, EC50: 5 nM
hEP3, EC50: 153 nM
    
CAY10535  
FP Receptor
 
TP Receptor
 
Prostaglandin F2α dimethyl amine  
FP
   
AMX12006 
hEP4, IC50: 4.3 nM
    
TG6-129 
EP
    
Prostaglandin D2-d4
DP
     
Saikogenin D 
EP
    99.99%
CAY10595
DP, Ki: 10 nM
     
Ramatroban-d4    
TXA2/TP
 
Latanoprost (Standard)  
FP Receptor
   
EP3 antagonist 6 
EP3, IC50: 1.9 nM
    
ICI 192605    
TXA2/TP
 
Etersalate    
TXA2
 
Terbogrel    
TXA2/TP
 
BM567    
TXA2 Receptor, IC50: 1.1 nM
TXA2 synthase, IC50: 12 nM
 
8-iso-15-keto Prostaglandin F2α  
FP
   
11-Deoxy-16,16-dimethyl-PGE2 
EP2
EP3
    
ER-819762 
EP4, IC50: 70 nM
    
Thromboxane A2    
TP
 
EP2 receptor agonist 4 
EP2, EC50: 43 nM
    
L 657925    
TXA2
 
Prostaglandin A3 
EP2, IC50: 120 nM
EP4, IC50: 20 nM
    
CAY10509  
FP, IC50: 30 nM
   
CRTH2-IN-1
hDP2, IC50: 6 nM
hDP1, IC50: 1 μM
     
LCB-2853    
TXA2 Receptor
 
AZ-1355   
Prostaglandin I2
TXA2/TP
 98.19%
RS-601    
TXA2 Receptor
 
CGS 15435    
TXA2, IC50: 1 nM
 
BGC-20-1531 
EP4
    
CI-949     
TXB2, IC50: 0.1 μM
YM158 free base    
TXA2 Receptor, pA2: 8.81
 
Bunaprolast     
TXB2
KF 13218     
TXB2, IC50: 5.3 nM